SiSaf gets green light from FDA for osteopetrosis treatment

SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.

Related Keywords

,Suzanne Saffie Siebert ,Sisaf Bio ,Autosomal Dominant Osteopetrosis Type ,Orphan Drug Designation ,Rare Pediatric Disease Designation ,Bio Developments ,Emerging Markets ,Fda ,Food And Drug Administration ,Fda Approval ,Clinical Trial ,Orphan Disease ,